The pharmacokinetics and safety of olaparib alone and with paclitaxel in Chinese patients with advanced solid tumour.

Trial Identifier: D081BC00002
Sponsor: AstraZeneca
NCTID:: NCT02430311
Start Date: June 2015
Primary Completion Date: July 2016
Study Completion Date: April 2017
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Beijing, China, 100021
China Beijing, China, 100071
China Hangzhou, China, 310003